Franziska M. Heydenreich

Dec 21, 2023 | science.org | Fernando Alvarez |Franziska M. Heydenreich |Brent A. Koscher

H. Holden Thorp [email protected] Info & AffiliationsLast week, Science reflected on major achievements in science in 2023, from weight loss drugs and a malaria vaccine to exascale computing and advances in artificial intelligence. These are all impressive developments and provide yet more testimony to the power of science to continually expand the quality of our lives while deepening our understanding of the world. Even so, it’s hard to end the year without some worries about 2024.

Dec 21, 2023 | science.org | Fernando Alvarez |Franziska M. Heydenreich |Brent A. Koscher |Corinne N. Simonti

Domestication What’s that growing under the bed? Corinne Simonti and Caroline AshSpores of P. cubensis (seen here in “psychedelic” colors) have been collected for clandestine magic mushroom cultivation over the past 50 years. PHOTO: TED KINSMAN/SCIENCE SOURCEMushrooms that produce the psychoactive compound psilocybin have been cultivated for decades, although the unlawful nature of their use has resulted in the origins of many strains being obscured. McTaggart et al.

Dec 21, 2023 | sciencemag.org | Fernando Alvarez |Franziska M. Heydenreich |Brent A. Koscher |Sibel Erduran

There is growing interest in the use of artificial intelligence (AI) in science education. Many issues and questions raised about the role of AI in science education target primarily science learning objectives. They relate to AI’s capacity to generate tools for teaching, learning, and assessment, as well as the advantages and disadvantages of using such tools.

Dec 21, 2023 | sciencemag.org | Fernando Alvarez |Franziska M. Heydenreich |Brent A. Koscher

Last week, Science reflected on major achievements in science in 2023, from weight loss drugs and a malaria vaccine to exascale computing and advances in artificial intelligence. These are all impressive developments and provide yet more testimony to the power of science to continually expand the quality of our lives while deepening our understanding of the world. Even so, it’s hard to end the year without some worries about 2024.

Dec 14, 2023 | science.org | Fernando Alvarez |Franziska M. Heydenreich |Brent A. Koscher

PerspectiveNeurodegenerationAntibodies targeting amyloid-β aggregates slow decline in Alzheimer’s diseaseTodd E. Golde [email protected] and Allan I. Levey [email protected] Info & AffiliationsThree monoclonal antibodies—aducanumab, lecanemab, and donanemab— that target amyloid-β (Aβ) deposits in the brain slow cognitive and functional decline in early Alzheimer’s disease (AD) (1–3).